Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74:229–63.

Thun M, Linet MS, Cerhan JR, Haiman CA, Schottenfeld D, editors. Cancer epidemiology and prevention. Oxford University Press; 2017. https://doi.org/10.1093/oso/9780190238667.001.0001.

Book  Google Scholar 

Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, et al. Oesophageal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:992–1004.

Article  PubMed  Google Scholar 

Shu Y, Wang J, Chen Z, Kim S‑B, Lin C‑Y, Kato K, et al. Concordance among three programmed death-ligand 1 (PD-L1) scoring methods and their association with clinical outcomes of tislelizumab (TIS) monotherapy in esophageal squamous cell carcinoma (ESCC). JCO. 2024;42:390–390.

Article  Google Scholar 

Ajani JA, Barthel JS, Bentrem DJ, D’Amico TA, Das P, Denlinger CS, et al. Esophageal and esophagogastric junction cancers. J Natl Compr Canc Netw. 2011;9:830–87.

Article  PubMed  Google Scholar 

Puhr HC, Prager GW, Ilhan-Mutlu A. How we treat esophageal squamous cell carcinoma. ESMO Open. 2023;8:100789.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Research C for DE and FDA. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. 2019. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication. Accessed 20 Apr 2024.

Keytruda | European medicines agency https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda. Accessed 2 May 2024.

Sun J‑M, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398:759–71.

Article  CAS  PubMed  Google Scholar 

Ronan KJ, Ajani Jaffer A, Kuzdzal J, Thomas Z, Van Cutsem E, Piessen G, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384:1191–203.

Article  Google Scholar 

di Pietro M, Canto MI, Fitzgerald RC. Endoscopic management of early adenocarcinoma and squamous cell carcinoma of the esophagus: screening, diagnosis, and therapy. Gastroenterology. 2018;154:421–36.

Article  PubMed  Google Scholar 

Eyck BM, van Lanschot JJB, Hulshof MCCM, van der Wilk BJ, Shapiro J, van Hagen P, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol. 2021;39:1995–2004.

Article  CAS  PubMed  Google Scholar 

Conroy T, Galais M‑P, Raoul J‑L, Bouché O, Gourgou-Bourgade S, Douillard J‑Y, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014;15:305–14.

Article  CAS  PubMed  Google Scholar 

de Vos-Geelen J, Hoebers FJP, Geurts SME, Hoeben A, de Greef BTA, Voncken FEM, et al. A national study to assess outcomes of definitive chemoradiation regimens in proximal esophageal cancer. Acta Oncol. 2020;59:895–903.

Article  CAS  PubMed  Google Scholar 

Shah MA, Sun J‑M, Shen L, Kato K, Enzinger PC, Adenis A, et al. First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5‑year outcomes from the phase 3 KEYNOTE-590 study. JCO. 2024;42:250–250.

Article  Google Scholar 

Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386:449–62.

Article  CAS  PubMed  Google Scholar 

Chau I, Ajani J, Doki Y, Xu J, Wyrwicz L, Motoyama S, et al. O‑3 Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648. Ann Oncol. 2022;33:S379–S80.

Article  Google Scholar 

Yap DWT, Leone AG, Wong NZH, Zhao JJ, Tey JCS, Sundar R, et al. Effectiveness of Immune Checkpoint Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma: A Meta-analysis Including Low PD-L1 Subgroups. JAMA Oncology. 2023;9:215–24.

Kato K, Cho BC, Takahashi M, Okada M, Lin C‑Y, Chin K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:1506–17.

Article  CAS  PubMed  Google Scholar 

Shen L, Kato K, Kim S‑B, Ajani JA, Zhao K, He Z, et al. Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-302): a randomized phase III study. J Clin Oncol. 2022;40:3065–76.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu C‑H, et al. Randomized phase III KEYNOTE-181 study of Pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38:4138–48.

Article  CAS  PubMed  Google Scholar 

Hubner_BGB-A317-306_ESMO_Poster_2023.pdf https://www.beigenemedical.com/CongressDocuments/Hubner_BGB-A317-306_ESMO_Poster_2023.pdf. Accessed 7 May 2024.

Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, et al. Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial. JAMA. 2021;326:916–25.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang Z‑X, Cui C, Yao J, Zhang Y, Li M, Feng J, et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. Cancer Cells. 2022;40:277–288.e3.

Article  CAS  Google Scholar 

Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ. 2022;377:e68714.

Article  PubMed  PubMed Central  Google Scholar 

Xu J, Kato K, Raymond E, Hubner RA, Shu Y, Pan Y, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2023;24:483–95.

Article  CAS  PubMed  Google Scholar 

Meng X, Zheng A, Wang J, Wu X, Li G, Zhu J, et al. Nimotuzumab plus concurrent chemo-radiotherapy in unresectable locally advanced oesophageal squamous cell carcinoma (ESCC): interim analysis from a Phase 3 clinical trial. Br J Cancer. 2023;129:1787–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hsu C‑H, Lu Z, Gao S, Wang J‑Y, Sun J‑M, Liu T, et al. SKYSCRAPER-08: a phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) + atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC). JCO. 2024;42:245–245.

Article  Google Scholar 

Kotani D, Yamaguchi K, Kato K, Hara H, Miura A, Satoh T, et al. A phase 2, open-label study of amivantamab in patients with previously treated advanced or metastatic gastric or esophageal cancer. JCO. 2024;42:363–363.

Article  Google Scholar 

ESCORT-NEO: pCR Data Favor Addition of Immunotherapy to Neoadjuvant Therapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma https://dailynews.ascopubs.org/doi/10.1200/ADN.24.201646. Accessed 21 Apr 2024.

Shah MA, Bennouna J, Doi T, Shen L, Kato K, Adenis A, et al. KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncol.17:1143–53.

Goodman KA, Xu R, Chau I, Chen MH, Cho BC, Shah MA, et al. SKYSCRAPER-07: a phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy. JCO. 2022;40:TPS374–TPS374.

Article  Google Scholar